The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial of eribulin for recurrent or metastatic salivary gland cancers.
 
Keith D. Eaton
Research Funding - Mirati Therapeutics (Inst); Pfizer (Inst); Resolution Bioscience (Inst)
 
Bernardo H. L. Goulart
No Relationships to Disclose
 
Rafael Santana-Davila
Consulting or Advisory Role - Eisai; Seagen
Research Funding - Genentech (Inst); Lilly (Inst)
 
Laura Quan Man Chow
Honoraria - Amgen; Astellas Pharma; Emergent BioSolutions; Merck; Novartis
Consulting or Advisory Role - Amgen; Emergent BioSolutions; Merck; Novartis
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Incyte (Inst); Lilly/ImClone (Inst); Merck (Inst); NCCN/Glaxo-Smith Kline (Inst); Novartis (Inst); Pfizer (Inst); VentiRx (Inst)
Travel, Accommodations, Expenses - Merck; Novartis
 
Rebecca L. Wood
Travel, Accommodations, Expenses - Clovis Oncology; Novartis
 
Cristina P. Rodriguez
Research Funding - Karyopharm Therapeutics (Inst); Merck (Inst)
 
Christina S. Baik
Consulting or Advisory Role - Novartis
Research Funding - Celgene (Inst); Clovis Oncology (Inst); Incyte (Inst); Millennium (Inst); Novartis (Inst)
 
Renato G. Martins
Research Funding - Eisai (Inst); Genentech (Inst); Lilly (Inst); Pfizer (Inst)